SOX9 (SRY-Box Transcription Factor 9)

Moreover, GSC-selective expression of a combination of cytotoxic (HSV-TK and ganciclovir) and immunomodulatory (IL-12) payloads, delivered using adeno-associated virus vectors, as a single treatment led to curative outcomes in a mouse model of aggressive glioblastoma...In summary, SSEs harness the unique core transcriptional programs that define the GSC phenotype and enable precision immune activation. This approach may have broader applications in other contexts when precise control of transgene expression in specific cell states is necessary.

Zebrafish with the MZ ewsr1a/ewsr1a genotype display an increased level of collagen type II protein in the notochord starting at 36 h post fertilization. We propose that Ewsr1a contributes to IVD formation by regulating the expression of col2a1a.

The mean of SOX 9 levels in tissues of high-grade serous carcinoma was 3.5±2.5 ng/mL as compared to 1.0±0.9 ng/mL in low-grade serous carcinoma. Interpretation and conclusions SOX9 appears to be an important player in the molecular tumourigenesis of ovarian cancer, particularly in high grade tumours.

Co-targeting SOX9 and YAP1 offers a promising and safe broad-spectrum preventive/therapeutic approach for iCCA, potentially overcoming resistance to YAP1 inhibition. The adaptive resistance mechanism identified may extend to other malignancies, providing insights for addressing the advanced resistant to YAP1-TEAD-directed therapies.

These changes promote the expansion of persister stem cells that help the intestine recover after radiation. This study shows how fasting and gut bacteria work together to protect healthy tissue and suggests that diet or microbial treatments could help reduce side effects of cancer radiotherapy.

In contrast, combined HCC-CCA (n=4) displayed oncogene alterations in known targets (TP53, BAP1 and TERT). Increased atypical ductular reactions in specimens of HCC-patients after transarterial embolization treatment can be identified as regenerative phenomenon with distinct morphology and immunophenotype.

Together these findings establish Plagl1 as a critical regulator of the late-stage RPC to Müller glia transition, acting through coordinated control of chromatin accessibility and gene expression programs to ensure timely cell cycle exit. This function aligns with Plagl1's broader tumor suppressor role in stabilizing postmitotic, differentiated cell states across tissues.

Our findings reveal that miR-19b-3p orchestrates tumor-endothelial interactions by synchronously promoting EMT and EndMT, thereby driving a pro-metastatic microenvironment. Circulating miR-19b-3p represents a promising biomarker and potential therapeutic target in metastatic colorectal cancer.

This study provides a comprehensive single-cell-based atlas of CSCs in HCC, highlighting their spatial niches, regulatory programs, and clinical relevance. The identified prognostic signature and candidate drugs offer promising avenues for CSC-targeted therapies.

These results highlight how crucial thorough molecular profiling is for improved categorization, prognostication, and the creation of focused treatment plans in GBM. The discovery of the dual functions of the PAX and SOX genes in GBM highlights their potential as therapeutic targets and biomarkers, opening up new possibilities for more individualised and accurate treatment approaches.

Activation of SOX9 through the APE1-redox function is a key driver of EAC chemoresistance. Targeting APE1's redox activity offers a promising therapeutic strategy to overcome resistance by inhibiting the otherwise "undruggable" SOX9 transcription network.